10-Q: Syra Health Reports Q3 Loss Narrows Amid Revenue Shift

Syra Health Corp. reported a reduced net loss for the third quarter and nine months ended September 30, 2025, despite an overall revenue decline and ongoing liquidity concerns.

Summary

• Net revenues for the three months ended September 30, 2025, decreased by 25% to $1,687,971 from $2,253,336 in the prior year.
• Net revenues for the nine months ended September 30, 2025, decreased by 8% to $5,491,944 from $5,975,357 in the prior year.
• The company's net loss for the three months ended September 30, 2025, significantly narrowed to $225,902, compared to a net loss of $417,535 in the same period of 2024.
• For the nine months ended September 30, 2025, the net loss improved substantially to $761,763, from $3,254,841 in the prior year.
• Gross profit margin increased to 33% for the three months and 35% for the nine months ended September 30, 2025, up from 30% and 22% respectively in 2024.
• Healthcare workforce revenue declined significantly, while population health revenue saw a substantial increase, reflecting a strategic shift in service mix.
• Operating expenses decreased due to headcount reductions, streamlining operations, and a significant drop in research and development expenses.
• The company voluntarily delisted its Class A common stock from the Nasdaq Capital Market on April 11, 2025, after failing to meet the minimum bid price requirement.
• Management identified substantial doubt about the company's ability to continue as a going concern for the next twelve months without additional capital.
• Cash and cash equivalents decreased to $1,976,545 as of September 30, 2025, from $2,395,405 at December 31, 2024.
• Working capital decreased to $2,156,762 as of September 30, 2025, from $2,739,246 at December 31, 2024.

Sentiment

Score: 4

Explanation: While the company significantly reduced its net loss and improved gross profit margins, overall revenue declined, and liquidity remains a major concern with a 'going concern' warning. The Nasdaq delisting and management changes add to the negative sentiment, despite operational improvements.

Positives

• Net loss for the three months ended September 30, 2025, decreased by $191,633, or 46%, to $225,902 compared to $417,535 in 2024.
• Net loss for the nine months ended September 30, 2025, decreased by $2,493,078, or 77%, to $761,763 compared to $3,254,841 in 2024.
• Gross profit margin increased to 33% for the three months and 35% for the nine months ended September 30, 2025, indicating improved profitability on services rendered.
• Operating loss significantly improved by $196,739 for the three months and $2,494,554 for the nine months ended September 30, 2025.
• Population health revenue increased by $627,713 (96%) for the three months and $2,547,991 (168%) for the nine months ended September 30, 2025, demonstrating growth in this segment.
• Net cash used in operating activities improved substantially to $158,554 for the nine months ended September 30, 2025, from $2,717,313 in the prior year, reflecting better working capital management and expense control.
• Salaries and benefits decreased by 43% for the three months and 46% for the nine months, due to headcount reduction and operational streamlining.

Negatives

• Total net revenues decreased by 25% for the three months and 8% for the nine months ended September 30, 2025, compared to the prior year.
• Healthcare workforce revenue declined by $1,169,828 (74%) for the three months and $2,986,059 (68%) for the nine months ended September 30, 2025.
• Behavioral and mental health services revenue ceased in 2025, down from $23,250 and $45,345 in the three and nine months of 2024, respectively.
• Cash and cash equivalents decreased by $418,860 from December 31, 2024, to September 30, 2025.
• Working capital decreased by $582,484 from December 31, 2024, to September 30, 2025.
• Accumulated deficit increased to $9,585,956 as of September 30, 2025, from $8,824,193 at December 31, 2024.
• Net cash provided by financing activities decreased significantly to a net use of $260,306 for the nine months ended September 30, 2025, from a net provision of $2,145,808 in the prior year.
• Professional fees increased by 25% for the three months and 19% for the nine months ended September 30, 2025, primarily due to increased legal and accounting fees.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern for the next twelve months.
• The company needs to raise substantial additional capital to fund its operations.
• Dependence on state, local, and county government budgets for revenue, which are subject to federal spending program changes.
• Delays in new contract awards or cancellations of previous requests for proposals due to federal government spending program pauses or terminations.
• Ability to compete in the healthcare industry, which is subject to competitive pressures including offerings and pricing.
• Risks associated with the timing, cost, and success or failure of new product and service introductions, development, and product upgrade releases.
• Potential for undetected errors or similar problems in software products.
• Compliance with existing laws, regulations, and industry initiatives, and future changes in healthcare industry laws or regulations.
• Possibility of services-related liabilities.
• Ability to obtain, maintain, and protect intellectual property rights and potential for substantial costs from lawsuits.
• Reliance on third-party content providers.
• Ability to expand the organization to accommodate potential growth and retain/attract key personnel.
• Successful development of sales and marketing capabilities.

Future Outlook

The company believes its existing liquidity and expected cash from sales will not be sufficient to fund operations for the next twelve months, necessitating additional equity and/or debt financing. There is no assurance that such financing will be available on favorable terms or at all. The company's ability to scale production and distribution is largely dependent on successfully raising additional capital. Federal government spending program changes are expected to negatively affect the quantity and timing of revenue in the near term.

Management Comments

• "We depend heavily on state, local and county government budgets for our revenue."
• "In 2025, the United States federal government began pausing or terminating numerous spending programs that potentially fund those programs and institutions that are our customers."
• "As such, we have begun to see delays in new contract awards, or cancellations of previous requests for proposals. These factors, and the possibility of further spending reviews and cancellations are expected to negatively affect the quantity and time of our revenue, results of operations and cash flows in the near term."
• "Our cost of services decreased primarily due to a decrease in labor costs, and decreased consulting costs associated with a change in service mix from healthcare workforce services to project-based population health and digital health services that carry better margins."
• "Salaries and benefits decreased as our headcount decreased in 2025, and due to a strategic focus on streamlining our operations by reducing redundancies and optimizing our workforce."
• "We believe that our existing sources of liquidity, along with cash expected to be generated from sales and services, will not be sufficient to fund our operations, anticipated capital expenditures, working capital and other financing requirements for at least the next twelve months from the issuance of the financial statements."
• "The Company continues to pursue sources of additional capital through debt and financing transactions or arrangements, including equity financing or other means."

Industry Context

The company operates in the healthcare services sector, which is heavily influenced by government funding and policy changes. The reported delays in contract awards and cancellations of proposals due to federal spending program changes indicate a challenging environment for companies reliant on public sector clients. The strategic shift from lower-margin healthcare workforce services to higher-margin population health and digital health services aligns with a broader industry trend towards value-based care and technology-driven solutions, potentially improving long-term profitability if successfully executed amidst funding uncertainties.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• A wrongful termination lawsuit filed by a former employee in January 2024 was settled for an immaterial amount in January 2025, and the case was dismissed.

Related Party Transactions

• The company leases its corporate headquarters from STVentures, LLC, an entity beneficially owned by its principal owners and management team. Rent expense for the nine months ended September 30, 2025, was $89,621.
• The company incurred $326,357 for IT services from RAD CUBE LLC, an entity beneficially owned by its principal owners and management team, for the nine months ended September 30, 2025.
• The company paid $195,428 for recruitment and human resource services from NLogix IT Services Private Limited and $121,129 from SKL Demand Private Limited, both entities beneficially owned by principal owners and management, for the nine months ended September 30, 2025.
• As of September 30, 2025, the company owed $57,167 in fees payable to directors, presented within accounts payable, related parties.
• An unpaid balance of $5,580 for office lease and $75,017 for IT services was outstanding to related parties at September 30, 2025.

Stakeholder Impact

• **Shareholders**: Face significant uncertainty due to the 'going concern' warning, Nasdaq delisting, and need for future capital raises, which could dilute existing shares. The improved net loss and gross margin are positive, but overall revenue decline is a concern.
• **Employees**: Headcount reductions and operational streamlining indicate potential job insecurity, though efforts to optimize the workforce could lead to a more stable long-term outlook if the company secures funding.
• **Customers**: Delays in new contract awards and potential cancellations of proposals due to federal spending changes could impact service delivery and relationships, particularly with government agencies.
• **Creditors**: The 'going concern' warning and need for additional financing raise concerns about the company's ability to meet future obligations, although current working capital is positive.
• **Management**: Significant changes at the CEO level and the appointment of an interim CEO indicate a period of transition and strategic re-evaluation, placing pressure on the current leadership team to stabilize operations and secure funding.

Next Steps

• Seek additional equity and/or debt financing to fund operations and address going concern issues.
• Continue to monitor expenditures and cash flow position.
• Focus on developing a new strategic plan and identifying and hiring a new CEO.
• Finalize terms for equity awards for the newly appointed director by December 31, 2025.

Key Dates

Recommendation

Despite a notable reduction in net loss and improved gross profit margins, the company faces severe challenges that warrant a 'strong sell' recommendation. The explicit 'going concern' warning, coupled with declining overall revenue, a significant drop in cash and working capital, and the voluntary delisting from Nasdaq, indicate substantial financial instability and high risk. The reliance on future capital raises, with no assurance of success, and the negative impact of federal spending cuts on contract awards, further compound the uncertainty. While operational efficiencies are being implemented, the fundamental liquidity and revenue generation issues present an unacceptable risk profile for investors.

Keywords

Healthcare services, Population health, Healthcare workforce, SEC filing, 10-Q, Financial results, Going concern, Nasdaq delisting, Management changes, Government contracts, Indiana FSSA, Financial performance, Operating loss, Net loss, Liquidity, Capital raise